Education


* 1971-B.A. Chemistry, University of California, Irvine
* 1971-B.A. Mathematics, University of California, Irvine
* 1974-M.A. Chemistry, University of California, Santa Barbara
* 1976-B.A. Biology, University of California, Irvine
* 1980-M.D. California College of Medicine, Irvine
* 1981-Surgery Internship, University of California, Davis
* 1982-Surgery Residency, University of California, Davis
* 1986-Otolaryngology Residency, University of California, Davis
* 1986-Maxillofacial Surgery Fellowship, University of California, Davis
* 1986-Facial Plastic and Reconstructive Surgery, Fellowship, University of California, Davis

Board Certification


* American Board of Otolaryngology- Head and Neck Surgery, 1987 Licensed to dispense hearing aids, 1995

Hospital Privileges


* Mercy Hospital of Folsom
* Marshall Medical Center, Placerville
* Folsom Surgery Center, Folsom

Addendum to Curriculum Vitae for James Yee, MD Research


* Primary Investigator: Eli Lilly
" XXXXX VS XXXXX in Difficult-to-Treat Acute Otitis Media"
* Primary Investigator: Daiichi
"A Phase III, Multienter, Randomized, Evaluator-Blind Study to Compare the Safety and Efficacy of Once Daily XXXXX with that of Four Times Daily XXXXX in the Treatment of Otitis Extern in Adolescent and Adult Subjects"
* Primary Investigator: Bayer Corporation

ACES 2000 Avelo Clinical Experience Study


* Primary Investigator: Aventis Pharmaceuticals

T.A.R.G.E.T. II The Allegra Research on Gaining Experience Trial II


* Primary Investigator: Aventis Pharmaceuticals

Randomized, Open-Label, Multicenter Trial of the Safety and Effectiveness of Oral XXXXX and XXXXX in Outpatients with Respiratory Tract Infections in Usual Care Settings

* Primary Investigator: Pfizer

A Multicenter, Open Label Trial Evaluation Oral Therapy with XXXXX 500 mg/Day for 3 Days (1.5 grams) and 500 mg/day for 6 days (3.0 grams) for the Treatment of Acute Bacterial Sinusitis

* Primary Investigator: Abbott Laboratories

An Open-Label, Safety and Efficacy Study of XXXXX Oral Suspension, 25 mg/kg Once Daily, in Pediatric Subjects with Acute Otitis Media

* Primary Investigator: Daiichi
"A Phase III, Mutlicenter, Open Label Study to Demonstrate the Safety and Efficay of Seven Days Once Daily XXXXX Otic Soluation 0.3% in the Treatment of Otitis Externa in Subjects 6 Months of Age or Older (Pediatric, Adolescent and Adult)
* Sub-Investigator: Daiichi
"A Multicenter Randomized Parallel Group Evaluator Blinded Comparative Study of the Safety and Efficacy of XXXXX and XXXXX in the Treatment of Acute Purulent Otorrhea in Pediatric Subjects with Tympanoplasty Tubes
* Sub-Investigator: Daiichi
"A Multicenter Prospective with Historical and Current Practice Control, Open Label to Study to Examine the Safety and Efficacy of XXXXX in the Treament Purulent Otorrhea in Adolescents and Adults with Chronic Perforation of Tympanic Membranes"